Cargando…

Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers

The proteins encoded by the excision repair cross-complementing (ERCC) family are pivotal in DNA damage repair and maintaining genome stability. However, the precise role of the ERCC family in tumor prognosis and the effectiveness of immune checkpoint inhibitors (ICI) therapy remain uncertain. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chao, Liu, Haozhen, Li, Yanlin, Liu, Jixian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457344/ https://www.ncbi.nlm.nih.gov/pubmed/37626083 http://dx.doi.org/10.1038/s41598-023-40185-7

Ejemplares similares

Association of PTPRT Mutations with Cancer Metastasis in Multiple Cancer Types
por: Chen, Chao, et al.
Publicado: (2022)

Associations of individual and joint expressions of ERCC6 and ERCC8 with clinicopathological parameters and prognosis of gastric cancer
por: Chen, Jing, et al.
Publicado: (2021)

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
por: Cheng, Lei, et al.
Publicado: (2022)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer
por: Wang, Shujie, et al.
Publicado: (2021)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
por: Lin, Anqi, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
por: Shang, Xiaoling, et al.
Publicado: (2023)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
por: Chen, Yu, et al.
Publicado: (2020)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
por: Cao, Jia-Zheng, et al.
Publicado: (2022)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Case Report: Lung adenocarcinoma associated with germline ERCC2 frameshift mutation
por: Liu, Lili, et al.
Publicado: (2023)

Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
por: Song, Ruixia, et al.
Publicado: (2023)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
por: Lin, Anqi, et al.
Publicado: (2021)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
por: Liu, Xueyong, et al.
Publicado: (2017)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma
por: Cui, Qing-ke, et al.
Publicado: (2014)

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
por: Zhang, Zhen, et al.
Publicado: (2021)

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
por: Ji, Wenxiang, et al.
Publicado: (2022)

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022)

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023)

Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Mao, Ziyang, et al.
Publicado: (2022)

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
por: Lin, Anqi, et al.
Publicado: (2022)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma
por: Cong, Tianhao, et al.
Publicado: (2022)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Two novel mutations in ERCC6 cause Cockayne syndrome B in a Chinese family
por: He, Chunxia, et al.
Publicado: (2017)

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
por: Wang, Yanni, et al.
Publicado: (2021)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
por: Mahzari, Moeber, et al.
Publicado: (2015)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Two heterozygous mutations in the ERCC6 gene associated with Cockayne syndrome in a Chinese patient
por: Zhang, Qin, et al.
Publicado: (2019)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
por: Vryza, Paraskevi, et al.
Publicado: (2023)

Gut microbial structural variation associates with immune checkpoint inhibitor response
por: Liu, Rong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hh1iv67lmo517p0j6429u8do91